• "Musings on open source and open standards in clinical trial software and healthcare IT"

  • Top Posts

  • Blog Post Categories

Using Patient-centered Technology to Improve Recruitment and Retention

Sponsors of clinical research must increasingly focus on improving patient engagement in order to meet many of today’s research challenges. Promising disruptions are already under way that could define new models for patient recruitment and retention.

In a time when drug development success is becoming scarcer and more expensive, the industry is looking everywhere it can for new, innovative approaches to improving health. Meeting recruitment goals is one of the biggest challenges for traditional clinical research. Less than one-third of people who come in for a screening end up completing a clinical trial.1 Thinking in a more patient-centric manner can help is in recruiting patients. A fundamental idea behind patient-centered research is to “amplify the patient’s role in the research process.”2 Employing new ways to engage patients and physicians while increasing their level of knowledge and trust can improve the sponsor’s ability to meet recruitment goals.

One often overlooked factor for study participation and retention is convenience. Raising the level of convenience for both the investigator and participant can eliminate a huge obstacle to non-participation or non-completion. There are many ways to incorporate increased levels of patient and physician convenience into trial design and execution, particularly using Internet-based technologies. For instance, social media can be an effective recruiting tool and an important way to build trust with targeted populations. Disease-specific online communities are becoming more and more prominent for chronic diseases. Matchmaking tools act as mediators that draw together researchers and participants. “Traditional” social media offers a less targeted, but no less effective, way to engage patients and investigators.

In general, the four key determinants of a person’s likelihood to participate in a trial are prior participation in research, existing relationships with researchers, involvement of trusted leaders, and trust in the organization. Keys to recruiting success in social media should keep these determinants in mind, and engage communities in a thoughtful, ethical way while respecting the norms of the community you are targeting.

Participant retention post-recruitment can be improved by strengthening the connections between participants and researchers, and enhancing communication structures to support these relationships.3 Capturing Patient Reported Outcomes electronically (ePRO), through the web or mobile devices, offers a way to interact with the participant in a meaningful way while also capturing critical data. For instance, offering the ePRO user risk scores and health recommendations based on their data, or using gamification techniques to increase protocol adherence, can enhance the traditional ePRO experience by offering direct, immediate value to the user. Enabling a “Bring Your Own Device” (BYOD) strategy can increase convenience for populations who already own their own smartphones or tablets. Of course, the study design and applicable regulatory considerations should drive when and how these techniques are used.

Increased focus on the patient experience is not a phenomenon unique to research, but something that is rapidly permeating healthcare systems. These rapid changes can enhance research engagement. There is enormous potential to capture far more robust data and have better follow up than ever before as widespread infrastructure is put in place for coordinated team-based care, home-based continuous monitoring, and wireless data reporting from medical devices. The (still elusive) promise of using the Electronic Health Record system in research to identify participants and capture clean, accurate trial data is more critical than ever before. As medical practices become more electronic and less paper-driven, investigators and staff should be engaged by providing them trial-specific information at the points in their workflow when they can best make use of it. Conversely, requiring them to go outside the workflows and systems they use in routine practice creates complexity and hassle that can deter research participation. A new level of integration between research and health data systems, based on standards (which exist) and open interfaces (which are coming, as part of Meaningful Use), will be necessary to make good on this potential.

As difficult research questions drive increased complexity in trial designs, many feel that the answer is to use technology in simple, scalable ways to engage more participants in research and capture more data. Dr. Russ Altman, a physician and Stanford professor recently told the New York Times, “There’s a growing sense in the field of informatics that we’ll take lots of data in exchange for perfectly controlled data. You can deal with the noise if the signal is strong enough.”4

References

1. Getz, Ken, The Gift of Participation: A Guide to Making Informed Decisions About Volunteering for a Clinical Trial, 2007, p40.

2. Pignone, Michael, MD, MPH, Challenges to Implementing Patient-Centered Research, Ann Intern Med. 18 September 2012;157(6):450-451

3. Nicholas Anderson, Caleb Bragg, Andrea Hartzler, Kelly Edwards, Participant-centric initiatives: Tools to facilitate engagement in research, Applied & Translational Genomics, Volume 1, 1 December 2012, Pages 25-29, ISSN 2212-0661, 10.1016/j.atg.2012.07.001.

4. http://www.nytimes.com/2013/01/15/health/mining-electronic-records-for-revealing-health-data.html?ref=health?src=dayp&_r=3&

Does EDC Help or Hurt Site Relations?

Getting reluctant clinical research sites to embrace technology such as electronic data capture (EDC) software can be difficult. This is a recipe for troubled relationships between the sponsor/CRO and sites. However, just as it is possible for a poor EDC implementation to erode sponsor-site relations, it is also possible for the EDC software to help cultivate improved relationships. Take a look at the new whitepaper, “Improving Site Relationships through EDC” to learn about some important considerations when thinking about site relations in the context of EDC.

The Evolution of Electronic Data Capture

OpenClinica was recently featured in an article in Genetic Engineering and Biotechnology News titled “Commandeering Data with EDC Systems,” written by Dr. James Netterwald. The article briefly recounts the early days of clinical trial Electronic Data Capture (EDC). But how far have we come? Dr. Netterwald’s title (perhaps unintentionally) conjures up images of struggle and strife, which may be perhaps more a more apropos description of the journey of Electronic Data Capture than it may first appear.

As an industry, it’s taken us a good 20 years to get to where we are, and to be plain, it’s been a slow start. (In my own defense, I, and my company Akaza Research, have only been a party to the industry for the last 5 of those 20 years.) Climbing the evolutionary ladder from shipping laptops to sites to keying data into electronic case report forms is certainly progress by any measure. However, while the days of mailing tapes and disks are over, the days of real electronic data capture are yet to come. Today, most experts agree that somewhere between only one-half and two-thirds of all new clinical trials use EDC software, an of this only a very small fraction are “e-source,” defined as collecting data in electronic form at its source as opposed to keying it in from some other source. In some ways it is ironic that cutting-edge biopharmaceutical technologies are developed themselves with technologies that are, relatively speaking, much further down the technology food chain.

Notwithstanding, there are some enterprising few who have pushed the pace towards true EDC. Spaulding Clinical, a large phase 1 unit in West Bend, Wisconsin has developed a system that automatically captures ECG data from their facility’s patients and directly populates the clinical trial database with these data. A patient wears the ECG device and the data are transmitted wirelessly to the EDC system. However, this slick and highly productive solution was not developed by either the ECG vendor or the EDC vendor. It was developed by hand by one of Spaulding’s own software developers.

Why isn’t this type of solution more commonplace in clinical trials? What prevents the industry from making the most of today’s information technology? With the strong incentives currently in place to make research more efficient, our field could certainly benefit from some more forward thinking.

- Ben Baumann

OpenClinica Community Surpasses 10,000 Members …and oh yeah, what is this open source thing?

Heartfelt thanks to everyone who has supported the OpenClinica project over its relatively brief history. Our community now stands at over 10,000 registered members, representing a 3-fold increase in size over the past two years alone. With members in over 70 countries across six continents, open source is now a central part of the clinical trials software landscape. This is a major accomplishment that we should all be proud of.

While 10,000 may sound like a lot of people, there are still many within the clinical trials industry who do not understand the key concepts of open source. Other software categories have a high prevalence of open source offerings. For instance, when you look at database products (like MySQL, Postgres) and operating systems (like Linux, Android, BSD) there are numerous open source options. Open source is even widely prevalent in the EMR/EHR space, with OpenVista, and over 20 others to choose from.

As OpenClinica ushers the benefits of open source into the clinical trials space, it is instructive to periodically revisit the fundamentals of what exactly open source is.

What is open source?

Open source is a type of free software license–free as in “freedom,” not “beer.”[1] It is not “freeware” and it is not “shareware.” More specifically, open source provides users with[2]:

  • The freedom to run a program, for any purpose
  • The freedom to study how a program works and adapt it to a person’s needs. (Access to the source code is a precondition for this.)
  • The freedom to redistribute copies so that you can help your neighbor.
  • The freedom to improve a program and release improvements to the public, so the whole community benefits. (Access to source code is a precondition for this.)

There are numerous open source software licenses based on the above tenants and roughly 60 open source licenses have been approved by the non-profit Open Source Initiative. The OpenClinica Community Edition is distributed under the LGPL open source license.

Open source as a development model

The software development models around open source projects are typically characterized by transparency and collaboration within the community. Opening the product up to the community, allowing anyone to see the good with the bad, helps to quickly uncover problems and identify areas for improvement. Most open source projects will publicly maintain a project roadmap and defect tracking system. Release cycles of active open source projects tend to be early and often.

The result of such openness and transparency is software that is often more reliable and better performing than proprietary, closed alternatives.

What is professional open source?

A symbiotic relationship exists in a health professional open source model between the Community, Company, and Customer.

Some people may think of open source projects as purely volunteer efforts. That is definitely not the case! While governance models vary from project to project, commercial enterprises have helped make open source consumable by ordinary people and businesses. For example, through its OpenClinica Enterprise Edition, Akaza Research provides support and regulatory assurances that help to minimize business risk and ensure success for organizations wishing to use OpenClinica in mission critical settings. Organizations can turn to Akaza to rapidly develop in-house expertise, obtain hosting and expert professional services, and ensure their OpenClinica systems and users are productive and satisfied.

A pervasive trend in software

Open source is everywhere[3]. From the Firefox web browser to the most popular websites, everyone who uses the World Wide Web uses open source. As web-based technology, OpenClinica and the OpenClinica community are direct beneficiaries of numerous other open source projects. Those within the clinical trials space who recognize the significance of open source will be a step ahead of their colleagues.

- Ben Baumann, Co-Founder, Akaza Research, LLC

Want to be an OpenClinica Community Member? Members get free access to OpenClinica software downloads, Issue Tracker, email forums, and the OpenClinica Case Report Form (CRF) Library. Register at http://www.openclinica.org/register.php.

Footnotes:
[1] See Open Source Software Definition, http://www.opensource.org/docs/osd
[2]From the Free Software Foundation: http://www.fsf.org/licensing/essays/free-sw.html
[3]The SourceForge repository of open source codebases counts over 230,000 OSS projects.

Selling open source without mentioning open source

I am a regular reader of  “The Open Road” blog by Matt Assay on news.com. In one of his latest posts, “Getting open-source criticism wrong”, he does a great job of making the case that commercial open source software is about ease of adoption, flexibility, and choice.

It struck a chord because my sales team and I spend a great amount of time and effort explaining to prospective customers that we offer the same level of quality, stability, performance, service, and support as a proprietary vendor. In many cases we must meet a higher threshold than those vendors, because we do not have the lock-in of a commercial software license to compel customers to come back to us for repeat business. Our track record of successful long-term customer relationship is evidence we meet this threshold.

In certain sales situations, for the sake of simplicity and clarity, we have to focus only on these apples-to-apples characteristics, and do not have the opportunity to educate on the economic and technical advantages of OSS as much as we would like. It’s great to know that our open source clinical data management software technology and service offerings can stand successfully on these merits. However, as many readers of this blog already know, open source offers an additional set of critical benefits: “the ability to adopt software rapidly and at low cost, the flexibility to develop and extend their systems as they choose, and the ability to reduce risk by obtaining paid commercial-grade [or better] support”. As more decision makers are coming to understand, it is following this path, rather than the adoption of pricey, monolithic proprietary software, that leads to better outcomes and greater ROI.

How Open Source EDC Can Make Clinical Trials More Productive

Barbara Zwick, from the European clinical trial Evidence and Performance Blog recently published an interview with Ben Baumann, Director of Business Development at Akaza Research. The interview discusses how open source EDC (Electronic Data Capture) clinical trials software can help enhance product time to market and overall productivity of clinical trials. Here are some excerpts from the interview:

[BZ] Today’s big Pharma R&Ds are increasing their demand for efficiency and effectiveness. How are you facing this accelerating demand for speed to market?

[BB] There are a number of ways that OpenClinica can accelerate time-to-market. First, open source software can be much easier and quicker to evaluate and get up and running than proprietary software. People can readily install it and experiment with it. Potential adopters can readily inspect everything down to the source code and directly interact with other members of the OpenClinica community to get rapid, unbiased, real-world feedback.

In addition to a full set of EDC and CDM features one might expect in such a system, OpenClinica has  built-in features that give users the ability to set-up their own studies. Therefore, an organization can get a complete picture of how well the system will work for them before committing to use it.

In short, an organization can make a rapid and highly informed decision whether or not to use OpenClinica without having to go through lengthy vendor-biased demonstrations and negotiations, and rely on a vendor in order to get their studies configured appropriately.

[BZ] How can technologies serve to clinical trial performance, to minimize costs and time to market, and to allow rapid decision making? Are innovative EDC technologies, like your platform, more performant and focused on this specific need, rather than ‘old-fashioned’ EDC Solutions?

[BB] Aside from features of the product and benefits of the open source model described above, Akaza Research’s business model for support is designed to maximize productivity of clinical trials. Our support is comprehensive and highly flexible, so customers are able to obtain support packages tailored to their needs. In addition, our customers find our support to be of extremely high quality-after all support is our primary source of revenue.

Most of our support isn’t priced “per study” so clients are able to amortize their investment over numerous studies and don’t have to go through a lengthy contracting process for each new clinical trial they want to use OpenClinica for. This can really help to minimize costs and accelerate the set-up time for new studies.

[BZ] What are the pro and cons of an open source technologies versus a classical technology in the SaaS model?

[BB] First, OpenClinica is available under both a SaaS model and local deployment. Open source has a number of benefits over “classical” proprietary EDC systems. Here are a few examples:

Reduce vendor lock-in. Numerous proprietary EDC companies have failed and gone out of business. Open source products exist and evolve independently of any particular vendor, so if one vendor ceases to exist, there are others readily available to take their place.

Improved security. Open source software is frequently more secure and bug free than proprietary software. The open source code is continuously (and often intensely) scrutinized by large community developers and security experts. As a result bugs and security issues are found and fixed usually before they become real problems.

Readily customizable. Open source systems can be readily customized and extended–you don’t need to rely on a vendor who may or may not make the software modifications you need. If the system doesn’t work the way to want it to, you can change it.

Enhanced validation. Validation can be much more thorough with open source software. Buying proprietary software is like buying a car with the  hood welded shut-you don’t know what’s really know going on behind the scenes. Open source provides the highest level of transparency making it possible to truly validate a system from end-to-end.

Microsoft Veteran Banks on Open Source

11-year Microsoft veteran, Keith Curtis, has recently published a book on Lulu.com called “After the Software Wars”. In it, Mr. Curtis describes how he believes open source will be the primary innovation engine for many long promised technological developments, such as cars that drive themselves. However, what is particularly interesting is the fact that Mr. Curtis built his career at Microsoft, a company that quite possibly views open source as its single largest threat.

While I haven’t read the book yet, the Web is already abound with abstracts and commentary, including a good summary posted on the New York Times blog by John Markoff. Here’s an excerpt:

“The key to faster technological progress is making software free,” he [Curtis] writes. “The difference between free, and non-free or proprietary software, is similar to the divide between science and alchemy. Before science, there was alchemy, where people guarded their ideas because they wanted to corner the market on the mechanisms used to convert lead into gold.”

He notes that there is an important parallel to the end of the Dark Ages, which came when society began to freely share advancements in math and science.

It is refreshing to see a man who spent 11 years enduring Microsoft propaganda still be able to think outside the confines of the proprietary software paradigm.

Why Pharmaceutical Companies Now Have a Reason to Choose Open Source

On October 27th, Bio-IT World published an article on the newly released OpenClinica 2.5. In a somewhat bold statement the article’s author stated that “Akaza Research has given pharmaceutical companies reason to take heed of the open source movement.” Akaza Research, of course, is the primary commercial force behind OpenClinica, the world’s most popular open source electronic data capture software.

What the author fails to explain, in my opinion, is why this is the case. For instance, I personally do not believe that the larger pharmaceutical companies would choose an open source EDC system for open source’s sake. In other words, the cost and flexibility benefits of open source, while significant, may not offer the same degree of value to Big Pharma as it would to myriad smaller companies. The industry’s largest firms have the financial resources and technical expertise to obtain and utilize essentially any solution in the marketplace and will therefore need a stronger motivation in order to move to open source. And I think that this motivation has to come from the quality of the technology and the overall solution through which it is implemented.

I do not believe OpenClinica would be making such a strong impact in such a short period of time if it weren’t for the robust open source community behind it. It is this community that provides fundamental value to the software. The decentralized efforts of users around the globe fuel OpenClinica’s evolution in a way that is both rapid and driven by true market demand from the trenches. The result is a product containing features that real-world users want and that work in the way these real world users want them to.

The open source community also helps to self-police the quality of OpenClinica distributions. There is a diverse group of users and developers who experiment with beta releases and continuously scour the system source code. From their unbridled vantage points within the community, these people report issues in a frank, public, and uncompromising manner. This transparency and candid public discourse about the software makes it difficult, if not impossible, to cut corners or sweep defects under the rug.

In a sense, with proprietary software you never really know what you’re getting. With open source software you know it all—both the good and the bad. It is the open source community that drives OpenClinica’s success, and this, in my opinion, is why pharmaceutical companies have reason to take heed of OpenClinica.

Why Open Source is Good for International Health Research (and Everyone Else)

A recent article titled, “Could an Open-Source Clinical Trial Data-Management System Be What We Have All Been Looking For?”, published in PLoS (Public Library of Science) proposes that “international health research organisations combine their efforts and spending power and assist with the development of systems that are open to all.” This is a bold statement with, in my opinion, solid rationale.
 

The authors, Greg W. Fegan and Trudie A. Lang, manage numerous clinical trials for the Kenya Medical Research Institute–Wellcome Trust Collaborative Research Programme in Kilifi, Kenya. Like many other research organizations in developing countries, their work largely focuses on finding treatments for “neglected diseases” such as malaria, hookworm, and encephalopathies. They clearly communicate the inability for proprietary eClinical software to be a widely useable solution in such settings due to costly and restrictive licensing. 
 

However, Fegan and Lang define the appeal of open source as something greater than financial savings (although this is a strong motivation). In addition to freedom from license fees, open source clinical trial software built with open components and open standards is more “modifiable and amenable for use with existing software already employed.” Perhaps the most significant point made is that open source can be a more powerful way to promulgate standards and better leverage the collective efforts of disparate research institutions.
 

Indeed, the authors also point out that the impact of a well designed and supported open source eClinical system “can be beneficial to all clinical researchers” and urge “international health research organisations to combine their efforts and spending power and assist with the development of systems that are open to all and truly fit for purpose.”
 

The paper closes with the following call to action:

“Research organisations and funders should combine efforts to produce an open-source solution for trial data management. A shared platform could then be easily established, and would bring wider benefits such as electronic submission to regulators, automated sharing of data, and contribution to important public databases such as pharmacovigilance and drug-monitoring registries.

We believe that an open-source approach to a truly designed-for-purpose data-management system for clinical trials is attractive. Such a system would save money by eliminating the reliance on the use of expensive database software systems and their administrators. This would empower and enable a wider variety of people to conduct trials, as the question of capturing, cleaning, and extracting data would not be overly daunting or expensive. This point is significant, as it may encourage more investigators in resource-poor settings to take part in high-standard research that would otherwise be out of reach and beyond their capacity. Surely this would increase the scope and variety of trials that are conducted. Our hope for this article is that it will begin a debate on this topic, and lead to a concerted effort to lobby the international research and donor community to make sure this barrier to trial conduct is understood and addressed.”

I encourage you to read the full article online at the PLoS website.

Follow

Get every new post delivered to your Inbox.

Join 1,596 other followers